Skip to Main Content

Project 2: Mechanism-based approaches to counter TKI resistance in EGFR mutant lung cancer

Targeted therapies have completely transformed the landscape for diagnosis and treatment of metastatic lung cancer. Despite this success, targeted therapies are not curative and acquired resistance is a major impediment to cures or durable responses for patients treated with these therapies. A paradigm for the success of targeted therapies in lung cancer, comes from Epidermal Growth Factor Receptor (EGFR) mutant lung cancer. Mutations in exons encoding the tyrosine kinase domain of EGFR are found in approximately 10-15% of lung adenocarcinomas in the US. These mutations confer sensitivity to tyrosine kinase inhibitors (TKIs) and four TKIs (erlotinib, gefitinib, afatinib and, most recently, osimertinib) are currently approved for the first-line treatment of EGFR mutant lung cancer. Acquired drug resistance, however, is a major challenge with all of these TKIs including osimertinib, but we have very limited knowledge of the mechanisms of resistance to osimertinib given its recent adoption in the clinic. Without knowledge about resistance mechanisms, optimal post-osimertinib treatment strategies remain to be defined. Data from our labs and others indicate that osimertinib resistance can arise through both EGFR-dependent mechanisms involving several different types of EGFR mutation and EGFR-independent mechanisms – frequently epigenetic in origin – that are poorly understood. Very little is known about the molecular context(s) in which these resistance mechanisms emerge, their frequency, biochemistry and how to target them pharmacologically. Given the speed of adoption of osimertinib as 1st line therapy, there is an urgent need to identify these mechanisms and resulting vulnerabilities. We propose to leverage our collective expertise in lung cancer biology, mouse models, resistance to targeted therapies and EGFR structural biology to address these issues. Using unique in vitro and in vivo models and patient resources of acquired resistance to osimertinib, innovative genomic and biochemical tools we will: 1) Identify molecular features and new therapeutic vulnerabilities of osimertinib-resistance EGFR variants. 2) Establish mutant EGFR heterodimerization patterns and determine whether these can be leveraged therapeutically to overcome osimertinib resistance; 3) Identify epigenetic processes that confer TKI resistance. Our studies will yield a comprehensive understanding of osimertinib resistance and insight with which to develop new mechanism-based approaches to target osimertinib-resistant tumors – an urgent unmet clinical need.


  • Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Medical Oncology-Hematology Program; Research Director, Center for Thoracic Cancers; Chief, Thoracic Oncology

    Research Interests
    • Carcinoma, Non-Small-Cell Lung
    • Immunotherapy
    • Lung
    • Medical Oncology
    • Thoracic Neoplasms
  • Alfred Gilman Professor and Chair of Pharmacology; Co-director, Cancer Biology Institute; Chair, Pharmacology

    Research Interests
    • Adenocarcinoma
    • Biochemistry
    • Cell Membrane
    • Crystallography
    • Protein-Tyrosine Kinases
    • Receptor Aggregation
    • Signal Transduction
    • Protein Structure, Tertiary
    • MAP Kinase Signaling System
    • Protein Kinase Inhibitors
    • ErbB Receptors
    • Single Molecule Imaging
    • Hydrogen Deuterium Exchange-Mass Spectrometry
  • Joseph A. and Lucille K. Madri Professor of Pathology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center; Scientific Director, Center for Thoracic Cancers

    Research Interests
    • Cell Transformation, Neoplastic
    • Lung Neoplasms
    • Pathology
    • Molecular Targeted Therapy